Eris Lifesciences forms JV with MJ Biopharm to enter India's insulin segment - BusinessToday

Diabetes Tips, News & Articles

Eris will now extend its product offering to insulins and GLP1 agonists. These categories comprise 61 per cent of the anti-diabetes market in the USA, ...
Eris will now extend its product offering to insulins and GLP1 agonists. These categories comprise 61 per cent of the anti-diabetes market in the USA, ...
Read more
Note: This news content is auto-generated from a syndicated feed.

If you have a family history of diabetes you could be at risk, get tested now! Book Diabetes test online

Popular posts from this blog

How the timing of dinner and genetics affect individuals' blood sugar control - ScienceDaily

Coronapod: COVID and diabetes, what the science says - Nature

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating ...